## <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# Materials

Antibodies	Yes (indicate where provided: page no/section/legend)	n/a
For commercial reagents, provide supplier		n/a
name, catalogue number and RRID, if available.		
Cell materials	Yes (indicate where provided: page no/section/legend)	n/a
<b>Cell lines:</b> Provide species information, strain.	5/Cell culture/ NCI-H1299 (ATCC, Cat# CRL-5803, RRID: CVCL_0060),	
Provide accession number in repository <b>OR</b>	A549 (ATCC, Cat# CCL-185, RRID: CVCL_0023), NCI-H460 (ATCC,	
supplier name, catalog number, clone number,	Cat# HTB-177, RRID: CVCL_0459), NCI-H358 (ATCC, Cat# CRL-5807,	
OR RRID	RRID:CVCL_1559), Hek293T (ATCC, Cat# CRL-3216, RRID: CVCL 0063)	
Primary cultures: Provide species, strain, sex of		n/a
origin, genetic modification status.		
Experimental animals	Yes (indicate where provided: page no/section/legend)	n/a
Laboratory animals: Provide species, strain, sex, age,		n/a
genetic modification status. Provide accession		
number in repository <b>OR</b> supplier name, catalog		
number, clone number, <b>OR</b> RRID		
Animal observed in or captured from the		n/a
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		n/a
in repository (where relevant) <b>OR</b> RRID		
Plants and microbes	Yes (indicate where provided: page no/section/legend)	n/a
Plants: provide species and strain, unique accession		n/a
number if available, and source (including location		
for collected wild specimens)		
Microbes: provide species and strain, unique		n/a
accession number if available, and source		
Human research participants	Yes (indicate where provided: page no/section/legend)	n/a
Identify authority granting ethics approval (IRB or	5/ Human tissue samples/The study was approved by Ethics	
equivalent committee(s), provide reference number	Committee of The Department of Lung Cancer at Shanghai Chest	
for approval.	Hospital, Shanghai Jiaotong University (No. XS2017-007).	
Provide statement confirming informed consent	5/ Human tissue samples/ written informed consent was obtained	
obtained from study participants.	from all patients.	
Report on age and sex for all study participants.		n/a

### <u>Design</u>

Study protocol	Yes (indicate where provided: page no/section/legend)	n/a
For clinical trials, provide the trial registration		n/a
number <b>OR</b> cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: page no/section/legend)	n/a
Provide DOI or other citation details if detailed step-		n/a
by-step protocols are available.		
Experimental study design (statistics details)	Yes (indicate where provided: page no/section/legend)	n/a
State whether and how the following have been		n/a
done <b>, or</b> if they were not carried out.		
Sample size determination		n/a
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria		n/a
Sample definition and in-laboratory replication	Yes (indicate where provided: page no/section/legend)	n/a
State number of times the experiment was		n/a
replicated in laboratory		
Define whether data describe technical or biological		n/a
replicates		
Ethics	Yes (indicate where provided: page no/section/legend)	n/a
Studies involving human participants: State details of	5/ Human tissue samples/The study was approved by Ethics	
authority granting ethics approval (IRB or equivalent	Committee of The Department of Lung Cancer at Shanghai Chest	
committee(s), provide reference number for approval.	Hospital, Shanghai Jiaotong University (No. XS2017-007).	
Studies involving experimental animals: State details		n/a
of authority granting ethics approval (IRB or		,.
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		n/a
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: page no/section/legend)	n/a
If study is subject to dual use research of concern,		n/a
state the authority granting approval and reference		

# <u>Analysis</u>

Attrition	Yes (indicate where provided: page no/section/legend)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		n/a
· · · · · · · · · · · · · · · · · · ·	1	
Statistics	Yes (indicate where provided: page no/section/legend)	n/a
Describe statistical tests used and justify choice of tests.		n/a
Data Availability	Yes (indicate where provided: page no/section/legend)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		n/a
If data are publicly available, provide accession number in repository or DOI or URL.		n/a
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	9/ LncRNA screening using Gene Expression Omnibus profiling datasets/ Two genomic profiling datasets (GSE102287, GSE13213) were analyzed with the online tool, "Analyze with 2R".	
Code Availability	Yes (indicate where provided: page no/section/legend)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	···· (································	n/a
State whether the code or software is available.		n/a
If code is publicly available, provide accession number in repository, or DOI or URL.		n/a

# **Reporting**

Adherence to community standards	Yes (indicate where provided: page no/section/legend)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		n/a
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	17/Footnote/ Reporting Checklist: The authors have completed the MDAR reporting checklist.	

Article information: http://dx.doi.org/10.21037/tcr-20-2147